Stem definition | Drug id | CAS RN |
---|---|---|
vinca alkaloids | 2827 | 71486-22-1 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1000 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 27 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 23 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.87 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 26 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 23, 1994 | FDA | PIERRE FABRE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 740.10 | 22.47 | 372 | 14902 | 73215 | 56203578 |
Disease progression | 597.55 | 22.47 | 365 | 14909 | 104808 | 56171985 |
Metastases to liver | 412.71 | 22.47 | 171 | 15103 | 21415 | 56255378 |
Metastases to bone | 398.33 | 22.47 | 162 | 15112 | 19346 | 56257447 |
Neutropenia | 392.91 | 22.47 | 332 | 14942 | 157835 | 56118958 |
Breast cancer metastatic | 341.81 | 22.47 | 136 | 15138 | 15333 | 56261460 |
Palmar-plantar erythrodysaesthesia syndrome | 298.14 | 22.47 | 135 | 15139 | 20930 | 56255863 |
Metastases to lung | 251.79 | 22.47 | 101 | 15173 | 11617 | 56265176 |
Neoplasm progression | 214.77 | 22.47 | 124 | 15150 | 31892 | 56244901 |
Metastases to lymph nodes | 198.49 | 22.47 | 75 | 15199 | 7348 | 56269445 |
Mucosal inflammation | 188.81 | 22.47 | 127 | 15147 | 42683 | 56234110 |
Breast cancer | 166.95 | 22.47 | 124 | 15150 | 48709 | 56228084 |
Metastases to central nervous system | 159.77 | 22.47 | 74 | 15200 | 12062 | 56264731 |
Neuropathy peripheral | 142.60 | 22.47 | 157 | 15117 | 102736 | 56174057 |
PIK3CA-activated mutation | 117.51 | 22.47 | 31 | 15243 | 927 | 56275866 |
Febrile neutropenia | 114.42 | 22.47 | 142 | 15132 | 105403 | 56171390 |
Pleural effusion | 99.09 | 22.47 | 119 | 15155 | 85361 | 56191432 |
Breast cancer recurrent | 97.56 | 22.47 | 38 | 15236 | 4037 | 56272756 |
Osteonecrosis of jaw | 92.79 | 22.47 | 75 | 15199 | 33283 | 56243510 |
Haematotoxicity | 91.65 | 22.47 | 45 | 15229 | 8338 | 56268455 |
Ejection fraction decreased | 90.14 | 22.47 | 60 | 15214 | 19781 | 56257012 |
Metastases to peritoneum | 89.98 | 22.47 | 33 | 15241 | 2971 | 56273822 |
Thrombocytopenia | 78.46 | 22.47 | 136 | 15138 | 136088 | 56140705 |
Tonsillar disorder | 77.45 | 22.47 | 23 | 15251 | 1067 | 56275726 |
Myelosuppression | 72.64 | 22.47 | 50 | 15224 | 17405 | 56259388 |
Blood uric acid decreased | 71.97 | 22.47 | 20 | 15254 | 730 | 56276063 |
Eosinophil percentage increased | 66.21 | 22.47 | 20 | 15254 | 984 | 56275809 |
Polyneuropathy | 65.47 | 22.47 | 42 | 15232 | 13008 | 56263785 |
Neurotoxicity | 65.15 | 22.47 | 45 | 15229 | 15750 | 56261043 |
Ascites | 63.90 | 22.47 | 64 | 15210 | 37480 | 56239313 |
Metastases to skin | 62.82 | 22.47 | 21 | 15253 | 1437 | 56275356 |
Fall | 60.16 | 22.47 | 12 | 15262 | 357498 | 55919295 |
Nasal disorder | 58.02 | 22.47 | 23 | 15251 | 2559 | 56274234 |
Bone marrow failure | 57.16 | 22.47 | 53 | 15221 | 28233 | 56248560 |
Off label use | 55.02 | 22.47 | 296 | 14978 | 555884 | 55720909 |
EGFR gene mutation | 53.52 | 22.47 | 13 | 15261 | 276 | 56276517 |
Death | 52.50 | 22.47 | 207 | 15067 | 341219 | 55935574 |
Drug hypersensitivity | 51.25 | 22.47 | 7 | 15267 | 275198 | 56001595 |
Neutropenic sepsis | 50.58 | 22.47 | 38 | 15236 | 15147 | 56261646 |
Joint swelling | 50.28 | 22.47 | 9 | 15265 | 289791 | 55987002 |
Osteonecrosis | 44.03 | 22.47 | 42 | 15232 | 23173 | 56253620 |
Tumour marker increased | 43.83 | 22.47 | 22 | 15252 | 4271 | 56272522 |
Decreased appetite | 42.14 | 22.47 | 143 | 15131 | 219088 | 56057705 |
Skin toxicity | 41.57 | 22.47 | 21 | 15253 | 4132 | 56272661 |
Therapy partial responder | 41.40 | 22.47 | 26 | 15248 | 7759 | 56269034 |
Hepatotoxicity | 40.43 | 22.47 | 46 | 15228 | 31107 | 56245686 |
Second primary malignancy | 40.06 | 22.47 | 25 | 15249 | 7377 | 56269416 |
Leukopenia | 39.71 | 22.47 | 70 | 15204 | 70870 | 56205923 |
Vessel puncture site bruise | 39.23 | 22.47 | 11 | 15263 | 415 | 56276378 |
Peripheral sensory neuropathy | 38.93 | 22.47 | 24 | 15250 | 6932 | 56269861 |
Hiccups | 38.79 | 22.47 | 16 | 15258 | 1972 | 56274821 |
Lymphangiosis carcinomatosa | 38.44 | 22.47 | 14 | 15260 | 1235 | 56275558 |
Blood creatinine decreased | 37.26 | 22.47 | 21 | 15253 | 5145 | 56271648 |
Arthralgia | 35.29 | 22.47 | 51 | 15223 | 501618 | 55775175 |
Hyperchlorhydria | 34.94 | 22.47 | 14 | 15260 | 1601 | 56275192 |
Abdominal discomfort | 34.58 | 22.47 | 16 | 15258 | 277258 | 55999535 |
Cardiotoxicity | 34.41 | 22.47 | 23 | 15251 | 7627 | 56269166 |
Joint neoplasm | 34.39 | 22.47 | 7 | 15267 | 63 | 56276730 |
Superior vena cava syndrome | 34.38 | 22.47 | 11 | 15263 | 655 | 56276138 |
Metastatic neoplasm | 34.02 | 22.47 | 18 | 15256 | 3895 | 56272898 |
Gastrointestinal toxicity | 33.84 | 22.47 | 21 | 15253 | 6135 | 56270658 |
Hypothalamo-pituitary disorder | 33.84 | 22.47 | 11 | 15263 | 689 | 56276104 |
Mediastinum neoplasm | 33.81 | 22.47 | 7 | 15267 | 69 | 56276724 |
Soft tissue neoplasm | 33.54 | 22.47 | 7 | 15267 | 72 | 56276721 |
Metastases to meninges | 33.51 | 22.47 | 15 | 15259 | 2255 | 56274538 |
Injection site extravasation | 33.00 | 22.47 | 23 | 15251 | 8161 | 56268632 |
Hormone receptor positive breast cancer | 32.91 | 22.47 | 10 | 15264 | 502 | 56276291 |
Blood lactate dehydrogenase increased | 32.90 | 22.47 | 34 | 15240 | 20641 | 56256152 |
Metastases to chest wall | 32.81 | 22.47 | 10 | 15264 | 507 | 56276286 |
Maternal exposure during pregnancy | 32.61 | 22.47 | 6 | 15268 | 189547 | 56087246 |
Metastases to spine | 32.53 | 22.47 | 16 | 15258 | 2973 | 56273820 |
Transaminases | 32.48 | 22.47 | 7 | 15267 | 85 | 56276708 |
Disease recurrence | 32.27 | 22.47 | 36 | 15238 | 23824 | 56252969 |
Diarrhoea | 32.06 | 22.47 | 288 | 14986 | 638219 | 55638574 |
Desmoplastic small round cell tumour | 31.88 | 22.47 | 8 | 15266 | 195 | 56276598 |
Invasive ductal breast carcinoma | 31.86 | 22.47 | 21 | 15253 | 6805 | 56269988 |
Osteolysis | 31.50 | 22.47 | 15 | 15259 | 2598 | 56274195 |
Pituitary tumour | 31.39 | 22.47 | 11 | 15263 | 868 | 56275925 |
Acquired gene mutation | 31.29 | 22.47 | 11 | 15263 | 876 | 56275917 |
Metastasis | 30.64 | 22.47 | 18 | 15256 | 4766 | 56272027 |
Constipation | 30.60 | 22.47 | 122 | 15152 | 201821 | 56074972 |
Sinusitis | 30.46 | 22.47 | 8 | 15266 | 197573 | 56079220 |
Diffuse large B-cell lymphoma recurrent | 30.46 | 22.47 | 13 | 15261 | 1744 | 56275049 |
Hepatic enzyme increased | 30.41 | 22.47 | 5 | 15269 | 171379 | 56105414 |
Pruritus | 30.17 | 22.47 | 25 | 15249 | 316598 | 55960195 |
Metastases to pleura | 29.97 | 22.47 | 12 | 15262 | 1370 | 56275423 |
Nail infection | 29.87 | 22.47 | 14 | 15260 | 2339 | 56274454 |
Nausea | 29.79 | 22.47 | 327 | 14947 | 763851 | 55512942 |
Condition aggravated | 29.59 | 22.47 | 30 | 15244 | 344868 | 55931925 |
Urticaria | 28.58 | 22.47 | 3 | 15271 | 144673 | 56132120 |
Jaw operation | 27.99 | 22.47 | 10 | 15264 | 835 | 56275958 |
Stomatitis | 27.91 | 22.47 | 84 | 15190 | 120726 | 56156067 |
Pancytopenia | 27.80 | 22.47 | 69 | 15205 | 88646 | 56188147 |
Folate deficiency | 27.78 | 22.47 | 13 | 15261 | 2164 | 56274629 |
Anaemia | 26.72 | 22.47 | 143 | 15131 | 267368 | 56009425 |
Musculoskeletal stiffness | 26.70 | 22.47 | 5 | 15269 | 156002 | 56120791 |
Asthenia | 26.30 | 22.47 | 171 | 15103 | 342802 | 55933991 |
Gene mutation | 26.04 | 22.47 | 11 | 15263 | 1438 | 56275355 |
Gingival bleeding | 25.79 | 22.47 | 23 | 15251 | 11643 | 56265150 |
Lymphoedema | 25.78 | 22.47 | 22 | 15252 | 10508 | 56266285 |
Dermatitis exfoliative generalised | 24.93 | 22.47 | 14 | 15260 | 3406 | 56273387 |
Cardiac cirrhosis | 24.46 | 22.47 | 6 | 15268 | 133 | 56276660 |
Drug resistance | 24.42 | 22.47 | 29 | 15245 | 20513 | 56256280 |
Toothache | 24.22 | 22.47 | 27 | 15247 | 17853 | 56258940 |
Nail avulsion | 24.00 | 22.47 | 6 | 15268 | 144 | 56276649 |
Scintillating scotoma | 23.77 | 22.47 | 6 | 15268 | 150 | 56276643 |
Eosinophil count increased | 23.32 | 22.47 | 20 | 15254 | 9617 | 56267176 |
Weight increased | 23.31 | 22.47 | 17 | 15257 | 229686 | 56047107 |
Hypertransaminasaemia | 23.23 | 22.47 | 15 | 15259 | 4692 | 56272101 |
Vascular device infection | 23.22 | 22.47 | 16 | 15258 | 5574 | 56271219 |
Postictal state | 23.12 | 22.47 | 9 | 15265 | 954 | 56275839 |
Mediastinal disorder | 22.85 | 22.47 | 7 | 15267 | 361 | 56276432 |
Odynophagia | 22.56 | 22.47 | 17 | 15257 | 6801 | 56269992 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neutropenia | 116.53 | 26.28 | 109 | 3536 | 140255 | 31553444 |
Febrile neutropenia | 72.23 | 26.28 | 79 | 3566 | 121770 | 31571929 |
Disease progression | 66.77 | 26.28 | 66 | 3579 | 90398 | 31603301 |
Off label use | 64.51 | 26.28 | 130 | 3515 | 347144 | 31346555 |
Malignant neoplasm progression | 62.71 | 26.28 | 60 | 3585 | 78938 | 31614761 |
Neutropenic sepsis | 59.94 | 26.28 | 29 | 3616 | 12350 | 31681349 |
Febrile bone marrow aplasia | 55.72 | 26.28 | 24 | 3621 | 7822 | 31685877 |
Pneumonitis | 46.72 | 26.28 | 34 | 3611 | 30618 | 31663081 |
Neoplasm progression | 39.11 | 26.28 | 26 | 3619 | 20246 | 31673453 |
Myelosuppression | 38.48 | 26.28 | 23 | 3622 | 14897 | 31678802 |
Toxic erythema of chemotherapy | 37.97 | 26.28 | 7 | 3638 | 92 | 31693607 |
Metastases to lung | 35.61 | 26.28 | 18 | 3627 | 8404 | 31685295 |
Leukopenia | 33.28 | 26.28 | 37 | 3608 | 57791 | 31635908 |
Product use in unapproved indication | 32.58 | 26.28 | 48 | 3597 | 99123 | 31594576 |
Product leakage | 32.20 | 26.28 | 8 | 3637 | 453 | 31693246 |
Interstitial lung disease | 29.82 | 26.28 | 36 | 3609 | 61367 | 31632332 |
Hypophosphataemia | 29.71 | 26.28 | 16 | 3629 | 8498 | 31685201 |
Diffuse large B-cell lymphoma refractory | 29.66 | 26.28 | 9 | 3636 | 1074 | 31692625 |
Agranulocytosis | 28.85 | 26.28 | 22 | 3623 | 21225 | 31672474 |
Pancytopenia | 28.28 | 26.28 | 42 | 3603 | 87274 | 31606425 |
Thrombocytopenia | 26.91 | 26.28 | 54 | 3591 | 142693 | 31551006 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 505.06 | 20.68 | 315 | 14550 | 121424 | 70792155 |
Neutropenia | 348.53 | 20.68 | 343 | 14522 | 256813 | 70656766 |
Disease progression | 323.04 | 20.68 | 265 | 14600 | 156407 | 70757172 |
Metastases to bone | 242.13 | 20.68 | 110 | 14755 | 22266 | 70891313 |
Breast cancer metastatic | 223.49 | 20.68 | 83 | 14782 | 10063 | 70903516 |
Metastases to lung | 213.67 | 20.68 | 92 | 14773 | 16392 | 70897187 |
Metastases to liver | 203.03 | 20.68 | 102 | 14763 | 25776 | 70887803 |
Neoplasm progression | 202.18 | 20.68 | 123 | 14742 | 45105 | 70868474 |
Palmar-plantar erythrodysaesthesia syndrome | 163.38 | 20.68 | 93 | 14772 | 30154 | 70883425 |
Mucosal inflammation | 150.54 | 20.68 | 120 | 14745 | 67730 | 70845849 |
Neuropathy peripheral | 127.99 | 20.68 | 145 | 14720 | 126751 | 70786828 |
Febrile neutropenia | 124.83 | 20.68 | 182 | 14683 | 204136 | 70709443 |
Metastases to lymph nodes | 121.13 | 20.68 | 52 | 14813 | 9186 | 70904393 |
Neutropenic sepsis | 114.69 | 20.68 | 69 | 14796 | 24761 | 70888818 |
Myelosuppression | 102.41 | 20.68 | 69 | 14796 | 30076 | 70883503 |
Breast cancer | 100.35 | 20.68 | 71 | 14794 | 33478 | 70880101 |
Metastases to central nervous system | 99.83 | 20.68 | 53 | 14812 | 14981 | 70898598 |
Breast cancer recurrent | 96.66 | 20.68 | 32 | 14833 | 2761 | 70910818 |
Tonsillar disorder | 83.24 | 20.68 | 23 | 14842 | 1071 | 70912508 |
Osteonecrosis of jaw | 81.37 | 20.68 | 68 | 14797 | 40934 | 70872645 |
PIK3CA-activated mutation | 77.32 | 20.68 | 19 | 14846 | 555 | 70913024 |
Haematotoxicity | 71.01 | 20.68 | 41 | 14824 | 13633 | 70899946 |
Bone marrow failure | 65.30 | 20.68 | 65 | 14800 | 48945 | 70864634 |
Ejection fraction decreased | 65.17 | 20.68 | 53 | 14812 | 30709 | 70882870 |
Blood uric acid decreased | 63.43 | 20.68 | 19 | 14846 | 1181 | 70912398 |
Thrombocytopenia | 62.71 | 20.68 | 148 | 14717 | 238962 | 70674617 |
Febrile bone marrow aplasia | 62.38 | 20.68 | 36 | 14829 | 11955 | 70901624 |
Metastases to peritoneum | 61.86 | 20.68 | 25 | 14840 | 3794 | 70909785 |
Eosinophil percentage increased | 59.89 | 20.68 | 19 | 14846 | 1431 | 70912148 |
Nasal disorder | 58.21 | 20.68 | 23 | 14842 | 3291 | 70910288 |
Off label use | 55.83 | 20.68 | 304 | 14561 | 742756 | 70170823 |
Therapy partial responder | 53.32 | 20.68 | 33 | 14832 | 12441 | 70901138 |
EGFR gene mutation | 52.31 | 20.68 | 13 | 14852 | 398 | 70913181 |
Fall | 50.90 | 20.68 | 15 | 14850 | 444081 | 70469498 |
Pancytopenia | 46.81 | 20.68 | 100 | 14765 | 151007 | 70762572 |
Pleural effusion | 43.56 | 20.68 | 90 | 14775 | 132774 | 70780805 |
Pneumonitis | 42.86 | 20.68 | 55 | 14810 | 54542 | 70859037 |
Metastases to skin | 42.62 | 20.68 | 15 | 14850 | 1556 | 70912023 |
Neurotoxicity | 42.41 | 20.68 | 41 | 14824 | 29785 | 70883794 |
Peripheral sensory neuropathy | 41.78 | 20.68 | 28 | 14837 | 12082 | 70901497 |
Vessel puncture site bruise | 40.59 | 20.68 | 11 | 14854 | 476 | 70913103 |
Hormone receptor positive breast cancer | 39.72 | 20.68 | 10 | 14855 | 323 | 70913256 |
Polyneuropathy | 39.37 | 20.68 | 34 | 14831 | 21381 | 70892198 |
Metastases to spine | 38.80 | 20.68 | 18 | 14847 | 3811 | 70909768 |
Joint neoplasm | 36.19 | 20.68 | 7 | 14858 | 63 | 70913516 |
Hepatotoxicity | 35.61 | 20.68 | 45 | 14820 | 43941 | 70869638 |
Leukopenia | 34.70 | 20.68 | 72 | 14793 | 106488 | 70807091 |
Invasive ductal breast carcinoma | 34.43 | 20.68 | 19 | 14846 | 5790 | 70907789 |
Nail infection | 34.31 | 20.68 | 14 | 14851 | 2177 | 70911402 |
Soft tissue neoplasm | 34.28 | 20.68 | 7 | 14858 | 85 | 70913494 |
Agranulocytosis | 33.85 | 20.68 | 42 | 14823 | 40256 | 70873323 |
Hyperchlorhydria | 33.08 | 20.68 | 13 | 14852 | 1833 | 70911746 |
Blood creatinine decreased | 32.83 | 20.68 | 20 | 14845 | 7329 | 70906250 |
Desmoplastic small round cell tumour | 32.74 | 20.68 | 8 | 14857 | 228 | 70913351 |
Lymphangiosis carcinomatosa | 32.71 | 20.68 | 13 | 14852 | 1888 | 70911691 |
Injection site extravasation | 32.06 | 20.68 | 21 | 14844 | 8725 | 70904854 |
Hypothalamo-pituitary disorder | 31.80 | 20.68 | 11 | 14854 | 1084 | 70912495 |
Drug hypersensitivity | 31.66 | 20.68 | 8 | 14857 | 262451 | 70651128 |
Nausea | 31.61 | 20.68 | 294 | 14571 | 851794 | 70061785 |
Pituitary tumour | 31.26 | 20.68 | 11 | 14854 | 1140 | 70912439 |
Arthralgia | 30.96 | 20.68 | 36 | 14829 | 503354 | 70410225 |
Metastases to the mediastinum | 30.44 | 20.68 | 9 | 14856 | 535 | 70913044 |
Metastatic neoplasm | 29.76 | 20.68 | 16 | 14849 | 4632 | 70908947 |
Disease recurrence | 29.69 | 20.68 | 38 | 14827 | 37565 | 70876014 |
Transaminases | 29.08 | 20.68 | 6 | 14859 | 77 | 70913502 |
Blood lactate dehydrogenase increased | 28.53 | 20.68 | 36 | 14829 | 35091 | 70878488 |
Mediastinum neoplasm | 28.21 | 20.68 | 6 | 14859 | 90 | 70913489 |
Acquired gene mutation | 28.12 | 20.68 | 12 | 14853 | 2086 | 70911493 |
Constipation | 28.11 | 20.68 | 116 | 14749 | 252322 | 70661257 |
Decreased appetite | 27.85 | 20.68 | 132 | 14733 | 304648 | 70608931 |
Non-small cell lung cancer recurrent | 27.67 | 20.68 | 6 | 14859 | 99 | 70913480 |
Gingival bleeding | 27.62 | 20.68 | 24 | 14841 | 15208 | 70898371 |
Gastrointestinal toxicity | 27.51 | 20.68 | 17 | 14848 | 6388 | 70907191 |
Nail avulsion | 27.29 | 20.68 | 6 | 14859 | 106 | 70913473 |
Toxic erythema of chemotherapy | 27.26 | 20.68 | 7 | 14858 | 245 | 70913334 |
Osteonecrosis | 27.11 | 20.68 | 32 | 14833 | 29128 | 70884451 |
Gene mutation | 27.11 | 20.68 | 12 | 14853 | 2279 | 70911300 |
Tumour marker increased | 26.96 | 20.68 | 14 | 14851 | 3780 | 70909799 |
Jaw operation | 26.81 | 20.68 | 9 | 14856 | 810 | 70912769 |
Joint swelling | 26.44 | 20.68 | 10 | 14855 | 253201 | 70660378 |
Diarrhoea | 26.41 | 20.68 | 265 | 14600 | 783076 | 70130503 |
Stomatitis | 25.80 | 20.68 | 72 | 14793 | 128439 | 70785140 |
Poor peripheral circulation | 25.16 | 20.68 | 13 | 14852 | 3472 | 70910107 |
Non-small cell lung cancer | 25.13 | 20.68 | 16 | 14849 | 6331 | 70907248 |
Ascites | 24.81 | 20.68 | 48 | 14817 | 67499 | 70846080 |
Hypotension | 24.76 | 20.68 | 29 | 14836 | 404352 | 70509227 |
Drug resistance | 24.67 | 20.68 | 35 | 14830 | 38155 | 70875424 |
Vaginal discharge | 24.59 | 20.68 | 14 | 14851 | 4529 | 70909050 |
Folate deficiency | 23.91 | 20.68 | 12 | 14853 | 3018 | 70910561 |
Primary mediastinal large B-cell lymphoma | 23.76 | 20.68 | 5 | 14860 | 71 | 70913508 |
Lower limb fracture | 23.73 | 20.68 | 23 | 14842 | 16749 | 70896830 |
Toothache | 23.72 | 20.68 | 24 | 14841 | 18406 | 70895173 |
Scintillating scotoma | 23.45 | 20.68 | 6 | 14859 | 207 | 70913372 |
Skin toxicity | 23.30 | 20.68 | 16 | 14849 | 7182 | 70906397 |
Cardiotoxicity | 23.28 | 20.68 | 19 | 14846 | 11051 | 70902528 |
Cardiac cirrhosis | 23.15 | 20.68 | 6 | 14859 | 218 | 70913361 |
Hypertransaminasaemia | 22.37 | 20.68 | 17 | 14848 | 8926 | 70904653 |
Cough | 22.20 | 20.68 | 130 | 14735 | 325247 | 70588332 |
Nail disorder | 22.15 | 20.68 | 18 | 14847 | 10406 | 70903173 |
Asthenia | 21.69 | 20.68 | 167 | 14698 | 457499 | 70456080 |
Urticaria | 21.62 | 20.68 | 4 | 14861 | 163045 | 70750534 |
Acute myeloid leukaemia | 20.94 | 20.68 | 29 | 14836 | 30911 | 70882668 |
Anaemia | 20.69 | 20.68 | 150 | 14715 | 403273 | 70510306 |
None
Source | Code | Description |
---|---|---|
ATC | L01CA04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues |
FDA CS | M0022674 | Vinca Alkaloids |
MeSH PA | D050256 | Antimitotic Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000972 | Antineoplastic Agents, Phytogenic |
MeSH PA | D050257 | Tubulin Modulators |
FDA EPC | N0000175612 | Vinca Alkaloid |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:47868 | photosensitising agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
Kaposi's sarcoma | off-label use | 109385007 | |
Neoplasm of endometrium | off-label use | 123844007 | DOID:1380 |
Small cell carcinoma of lung | off-label use | 254632001 | DOID:5409 |
Metastatic Breast Carcinoma | off-label use | ||
Disorder of lung | contraindication | 19829001 | DOID:850 |
Infectious disease | contraindication | 40733004 | |
Gastrointestinal perforation | contraindication | 51875005 | |
Hepatic failure | contraindication | 59927004 | |
Interstitial pneumonia | contraindication | 64667001 | |
Intestinal obstruction | contraindication | 81060008 | DOID:8437 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Pregnancy, function | contraindication | 289908002 | |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Hepatic Metastases | contraindication | ||
Intestinal Ischemic Necrosis | contraindication | ||
Severe Granulocytopenia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.32 | acidic |
pKa2 | 13.35 | acidic |
pKa3 | 8.55 | Basic |
pKa4 | 7.39 | Basic |
pKa5 | 6.11 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tubulin beta | Tumour-associated antigen | INHIBITOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
Substance-K receptor | GPCR | Ki | 6.27 | DRUG MATRIX |
ID | Source |
---|---|
4023981 | VUID |
N0000021986 | NUI |
D01935 | KEGG_DRUG |
125317-39-7 | SECONDARY_CAS_RN |
4020895 | VANDF |
4023981 | VANDF |
C0078257 | UMLSCUI |
CHEBI:480999 | CHEBI |
GDF | PDB_CHEM_ID |
CHEMBL553025 | ChEMBL_ID |
CHEMBL538943 | ChEMBL_ID |
CHEMBL3039595 | ChEMBL_ID |
D000077235 | MESH_DESCRIPTOR_UI |
DB00361 | DRUGBANK_ID |
7105 | IUPHAR_LIGAND_ID |
6054 | INN_ID |
Q6C979R91Y | UNII |
5311497 | PUBCHEM_CID |
114527 | RXNORM |
2135 | MMSL |
46388 | MMSL |
5676 | MMSL |
d03810 | MMSL |
004380 | NDDF |
004381 | NDDF |
108792008 | SNOMEDCT_US |
108794009 | SNOMEDCT_US |
372541004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vinorelbine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-204 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
Vinorelbine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45963-607 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 19 sections |
Vinorelbine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45963-607 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 19 sections |